 Leonard Seibold
Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 35 | 2025 | 219 | 8.260 |
Why?
| | Intraocular Pressure | 46 | 2025 | 297 | 7.040 |
Why?
| | Glaucoma, Open-Angle | 20 | 2023 | 101 | 6.600 |
Why?
| | Trabeculectomy | 16 | 2025 | 71 | 4.520 |
Why?
| | Phacoemulsification | 13 | 2025 | 115 | 3.850 |
Why?
| | Cataract | 10 | 2023 | 208 | 2.790 |
Why?
| | Ocular Hypertension | 7 | 2022 | 66 | 2.640 |
Why?
| | Glaucoma Drainage Implants | 10 | 2024 | 46 | 2.400 |
Why?
| | Tonometry, Ocular | 22 | 2022 | 88 | 2.000 |
Why?
| | Visual Acuity | 12 | 2024 | 321 | 1.970 |
Why?
| | Pilocarpine | 2 | 2025 | 15 | 1.550 |
Why?
| | Trabecular Meshwork | 7 | 2019 | 79 | 1.530 |
Why?
| | Glaucoma, Angle-Closure | 2 | 2020 | 16 | 1.270 |
Why?
| | Ophthalmology | 4 | 2023 | 82 | 1.140 |
Why?
| | Cataract Extraction | 5 | 2020 | 97 | 1.110 |
Why?
| | Laser Therapy | 3 | 2018 | 131 | 1.070 |
Why?
| | Ophthalmic Solutions | 6 | 2018 | 75 | 0.880 |
Why?
| | Filtering Surgery | 6 | 2016 | 22 | 0.860 |
Why?
| | Antihypertensive Agents | 5 | 2017 | 485 | 0.840 |
Why?
| | Lens Implantation, Intraocular | 3 | 2018 | 59 | 0.820 |
Why?
| | Nerve Fibers | 2 | 2012 | 89 | 0.730 |
Why?
| | Perception | 3 | 2021 | 337 | 0.720 |
Why?
| | Retinal Ganglion Cells | 2 | 2012 | 98 | 0.710 |
Why?
| | Tomography, Optical Coherence | 2 | 2012 | 186 | 0.670 |
Why?
| | Burnout, Professional | 2 | 2025 | 404 | 0.660 |
Why?
| | Stents | 4 | 2021 | 502 | 0.660 |
Why?
| | Laser Coagulation | 3 | 2023 | 57 | 0.650 |
Why?
| | Legislation, Drug | 1 | 2020 | 77 | 0.650 |
Why?
| | Postoperative Period | 7 | 2025 | 329 | 0.640 |
Why?
| | Specialization | 1 | 2020 | 144 | 0.630 |
Why?
| | Remote Sensing Technology | 1 | 2019 | 16 | 0.620 |
Why?
| | Ciliary Body | 2 | 2018 | 33 | 0.610 |
Why?
| | Aged, 80 and over | 14 | 2025 | 7055 | 0.600 |
Why?
| | Medical Marijuana | 1 | 2020 | 111 | 0.590 |
Why?
| | Angiogenesis Inhibitors | 5 | 2020 | 220 | 0.580 |
Why?
| | Retrospective Studies | 22 | 2025 | 14461 | 0.580 |
Why?
| | Brimonidine Tartrate | 1 | 2017 | 9 | 0.550 |
Why?
| | Thiazines | 1 | 2017 | 9 | 0.550 |
Why?
| | Humans | 63 | 2025 | 129271 | 0.540 |
Why?
| | Timolol | 1 | 2017 | 14 | 0.540 |
Why?
| | Marijuana Use | 1 | 2020 | 192 | 0.540 |
Why?
| | Marijuana Smoking | 1 | 2020 | 247 | 0.530 |
Why?
| | Prospective Studies | 11 | 2021 | 7123 | 0.530 |
Why?
| | Preservatives, Pharmaceutical | 2 | 2013 | 26 | 0.520 |
Why?
| | Aged | 20 | 2025 | 22032 | 0.510 |
Why?
| | Sulfonamides | 2 | 2017 | 495 | 0.510 |
Why?
| | Endoscopy | 2 | 2018 | 285 | 0.510 |
Why?
| | Corneal Diseases | 1 | 2016 | 34 | 0.500 |
Why?
| | Endophthalmitis | 1 | 2016 | 28 | 0.500 |
Why?
| | Circadian Rhythm | 2 | 2023 | 413 | 0.490 |
Why?
| | Minimally Invasive Surgical Procedures | 4 | 2024 | 170 | 0.480 |
Why?
| | Middle Aged | 21 | 2025 | 31091 | 0.450 |
Why?
| | Ocular Hypotension | 3 | 2022 | 10 | 0.440 |
Why?
| | Cloprostenol | 1 | 2013 | 13 | 0.430 |
Why?
| | Physicians | 1 | 2022 | 859 | 0.430 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1367 | 0.430 |
Why?
| | Prosthesis Implantation | 4 | 2022 | 143 | 0.420 |
Why?
| | Benzalkonium Compounds | 1 | 2012 | 15 | 0.400 |
Why?
| | Drug Combinations | 3 | 2020 | 330 | 0.400 |
Why?
| | Male | 27 | 2025 | 63517 | 0.380 |
Why?
| | Female | 28 | 2025 | 68556 | 0.380 |
Why?
| | Treatment Outcome | 13 | 2025 | 10202 | 0.360 |
Why?
| | Adipocytes | 1 | 2012 | 204 | 0.360 |
Why?
| | Wound Healing | 2 | 2012 | 306 | 0.350 |
Why?
| | Blood Pressure | 2 | 2017 | 1736 | 0.340 |
Why?
| | Stainless Steel | 1 | 2010 | 21 | 0.340 |
Why?
| | Optic Disk | 1 | 2010 | 40 | 0.340 |
Why?
| | Contact Lenses | 2 | 2020 | 9 | 0.330 |
Why?
| | Uveitis | 2 | 2022 | 127 | 0.330 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 2054 | 0.310 |
Why?
| | Follow-Up Studies | 6 | 2025 | 4887 | 0.290 |
Why?
| | Prednisolone | 2 | 2020 | 82 | 0.290 |
Why?
| | Software | 1 | 2012 | 606 | 0.280 |
Why?
| | Vision Disorders | 2 | 2020 | 135 | 0.270 |
Why?
| | Adult | 16 | 2025 | 35497 | 0.250 |
Why?
| | Reproducibility of Results | 4 | 2024 | 3080 | 0.250 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5051 | 0.240 |
Why?
| | Optometrists | 1 | 2025 | 4 | 0.240 |
Why?
| | Optometry | 1 | 2025 | 6 | 0.240 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.240 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 16 | 0.240 |
Why?
| | Sleep | 2 | 2023 | 684 | 0.240 |
Why?
| | Postoperative Care | 2 | 2025 | 241 | 0.230 |
Why?
| | Alkylating Agents | 2 | 2016 | 24 | 0.230 |
Why?
| | Glaucoma, Neovascular | 2 | 2015 | 10 | 0.230 |
Why?
| | Glucocorticoids | 2 | 2020 | 578 | 0.220 |
Why?
| | Macular Edema | 1 | 2023 | 43 | 0.210 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 5384 | 0.210 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 81 | 0.200 |
Why?
| | Communication Barriers | 1 | 2023 | 98 | 0.190 |
Why?
| | Diabetic Retinopathy | 1 | 2023 | 177 | 0.180 |
Why?
| | Heart Rate | 2 | 2017 | 802 | 0.180 |
Why?
| | Manometry | 1 | 2021 | 91 | 0.180 |
Why?
| | Cyclopentolate | 1 | 2020 | 3 | 0.180 |
Why?
| | Microscopy, Acoustic | 1 | 2020 | 8 | 0.180 |
Why?
| | Gonioscopy | 1 | 2020 | 6 | 0.170 |
Why?
| | Administration, Ophthalmic | 1 | 2020 | 15 | 0.170 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.170 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 372 | 0.170 |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 27 | 0.170 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2020 | 530 | 0.170 |
Why?
| | Amyloidosis | 1 | 2020 | 42 | 0.170 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2020 | 38 | 0.170 |
Why?
| | Health Status Disparities | 1 | 2023 | 251 | 0.170 |
Why?
| | Language | 1 | 2023 | 283 | 0.170 |
Why?
| | Visual Fields | 1 | 2020 | 87 | 0.170 |
Why?
| | Eye Diseases | 1 | 2020 | 81 | 0.160 |
Why?
| | Retinal Diseases | 1 | 2020 | 86 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 2 | 2014 | 3386 | 0.160 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 399 | 0.160 |
Why?
| | United States | 5 | 2025 | 13828 | 0.160 |
Why?
| | Intraoperative Complications | 1 | 2020 | 129 | 0.160 |
Why?
| | Preoperative Period | 1 | 2019 | 114 | 0.150 |
Why?
| | Young Adult | 6 | 2025 | 12392 | 0.150 |
Why?
| | Mitomycin | 2 | 2016 | 32 | 0.150 |
Why?
| | Biosensing Techniques | 1 | 2020 | 118 | 0.150 |
Why?
| | Axial Length, Eye | 1 | 2018 | 15 | 0.150 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.150 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 15 | 0.150 |
Why?
| | Pseudophakia | 1 | 2018 | 11 | 0.150 |
Why?
| | Uveitis, Anterior | 1 | 2018 | 13 | 0.150 |
Why?
| | Time Factors | 2 | 2019 | 6543 | 0.150 |
Why?
| | Refraction, Ocular | 1 | 2018 | 36 | 0.140 |
Why?
| | Intravitreal Injections | 4 | 2020 | 56 | 0.140 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 17 | 0.130 |
Why?
| | Healthcare Disparities | 1 | 2023 | 575 | 0.130 |
Why?
| | Equipment Design | 1 | 2018 | 513 | 0.130 |
Why?
| | Fluoroquinolones | 1 | 2016 | 45 | 0.130 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 333 | 0.130 |
Why?
| | Coronary Artery Disease | 1 | 2022 | 679 | 0.120 |
Why?
| | Lasers, Semiconductor | 1 | 2015 | 12 | 0.120 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 107 | 0.120 |
Why?
| | Drug Packaging | 1 | 2015 | 41 | 0.120 |
Why?
| | Device Removal | 1 | 2016 | 136 | 0.120 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2014 | 57 | 0.110 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2014 | 11 | 0.110 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 21 | 0.110 |
Why?
| | Travoprost | 1 | 2013 | 13 | 0.110 |
Why?
| | Patient Preference | 1 | 2016 | 184 | 0.110 |
Why?
| | Antimetabolites | 1 | 2012 | 23 | 0.100 |
Why?
| | Quality of Life | 1 | 2024 | 2687 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 648 | 0.100 |
Why?
| | Anterior Chamber | 1 | 2012 | 22 | 0.100 |
Why?
| | Telemedicine | 1 | 2021 | 789 | 0.100 |
Why?
| | Adenoma | 1 | 2014 | 214 | 0.090 |
Why?
| | Conjunctiva | 1 | 2012 | 51 | 0.090 |
Why?
| | Blister | 1 | 2012 | 41 | 0.090 |
Why?
| | Prostaglandins F | 1 | 2011 | 17 | 0.090 |
Why?
| | Electromagnetic Fields | 1 | 2010 | 23 | 0.090 |
Why?
| | Equipment Safety | 1 | 2010 | 37 | 0.090 |
Why?
| | Medication Adherence | 1 | 2015 | 556 | 0.090 |
Why?
| | Torque | 1 | 2010 | 82 | 0.080 |
Why?
| | Tissue Donors | 1 | 2012 | 391 | 0.080 |
Why?
| | Dexamethasone | 1 | 2012 | 350 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1040 | 0.080 |
Why?
| | Cell Survival | 1 | 2012 | 1075 | 0.080 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2439 | 0.080 |
Why?
| | Reference Values | 1 | 2010 | 793 | 0.080 |
Why?
| | Cohort Studies | 1 | 2019 | 5409 | 0.080 |
Why?
| | Adolescent | 4 | 2020 | 20315 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 854 | 0.070 |
Why?
| | Inflammation | 1 | 2018 | 2737 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2016 | 1708 | 0.060 |
Why?
| | Administration, Topical | 2 | 2016 | 145 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2012 | 2375 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2012 | 4077 | 0.060 |
Why?
| | Sickness Impact Profile | 1 | 2024 | 55 | 0.060 |
Why?
| | Safety-net Providers | 1 | 2023 | 109 | 0.050 |
Why?
| | Rabbits | 2 | 2012 | 777 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2024 | 632 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2022 | 305 | 0.040 |
Why?
| | Postoperative Complications | 2 | 2021 | 2473 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 504 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 252 | 0.040 |
Why?
| | Prevalence | 1 | 2025 | 2554 | 0.040 |
Why?
| | Histological Techniques | 1 | 2018 | 40 | 0.040 |
Why?
| | Reoperation | 1 | 2020 | 541 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 3233 | 0.040 |
Why?
| | Perioperative Care | 1 | 2019 | 151 | 0.040 |
Why?
| | Microscopy | 1 | 2018 | 141 | 0.030 |
Why?
| | Pharmaceutical Preparations | 1 | 2019 | 171 | 0.030 |
Why?
| | Fibrosis | 1 | 2018 | 520 | 0.030 |
Why?
| | Medication Errors | 1 | 2015 | 95 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 265 | 0.030 |
Why?
| | Iris | 1 | 2013 | 19 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1584 | 0.030 |
Why?
| | Disease Progression | 1 | 2020 | 2630 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1482 | 0.020 |
Why?
| | Goblet Cells | 1 | 2012 | 18 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 483 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 3773 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 296 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2012 | 172 | 0.020 |
Why?
| | Collagen | 1 | 2012 | 433 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2011 | 0.020 |
Why?
| | Animals | 3 | 2012 | 35309 | 0.020 |
Why?
| | Child | 1 | 2020 | 20785 | 0.010 |
Why?
|
|
Seibold's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|